Headlines about Acceleron Pharma (NASDAQ:XLRN) have trended somewhat positive on Thursday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Acceleron Pharma earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.2214487301896 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern’s rankings:
- Zacks: Analysts Expect Acceleron Pharma Inc (XLRN) Will Post Quarterly Sales of $4.35 Million (americanbankingnews.com)
- Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 Trial (finance.yahoo.com)
- Acceleron Pharma Inc (XLRN) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com)
- Acceleron Pharma Inc (XLRN) Director Richard F. Pops Sells 37,500 Shares (americanbankingnews.com)
Shares of Acceleron Pharma (XLRN) opened at $44.23 on Thursday. Acceleron Pharma has a 1 year low of $24.37 and a 1 year high of $46.93. The company has a market cap of $2,000.00, a P/E ratio of -16.44 and a beta of 1.39.
A number of equities analysts have weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $62.00 target price on shares of Acceleron Pharma in a research note on Wednesday, February 28th. Barclays boosted their target price on shares of Acceleron Pharma from $50.00 to $54.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 28th. Piper Jaffray Companies boosted their target price on shares of Acceleron Pharma to $53.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 28th. Credit Suisse Group reaffirmed a “buy” rating and issued a $55.00 target price on shares of Acceleron Pharma in a research note on Friday, March 2nd. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a research note on Monday, January 8th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $47.06.
In related news, Director Jean George sold 105,122 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $35.73, for a total transaction of $3,756,009.06. Following the completion of the transaction, the director now owns 1,250 shares in the company, valued at $44,662.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Christopher Rovaldi sold 2,266 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $42.42, for a total transaction of $96,123.72. Following the transaction, the senior vice president now owns 52,977 shares of the company’s stock, valued at approximately $2,247,284.34. The disclosure for this sale can be found here. In the last quarter, insiders have sold 183,521 shares of company stock valued at $7,082,848. 3.90% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Acceleron Pharma (XLRN) Given Daily Media Impact Score of 0.12” was first posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://baseballnewssource.com/2018/03/15/acceleron-pharma-xlrn-given-daily-media-impact-score-of-0-12/2036750.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.